Celtrix Pharmaceuticals, Inc.

Christopher A Maack

Andreas Sommer

Howard R Higley

Joseph A Carlino

Treatment with IGF/IGFBP-3 complex increases renal tubular mass and potentiates and/or stimulates kidney function in subjects suffering from acute and chronic renal failure or insufficiency resulting from such disorders as glomerulonephritis, glomerulosclerosis, interstitial nephritis, acute tubular necrosis due to ischemia and drug-induced toxicity, diabetic and autoimmune nephropathies and renal dysfunction due to acute and chronic rejection episodes in post-transplantation patients.

Method of treating renal disease by administering IGF-I and IGFBP-3

This is a method for treating catabolic conditions in individuals by administering a composition containing a complex of insulin-like growth factor (IGF) and insulin-like growth factor binding protein-3 (IGFBP-3).

Method for treating catabolic conditions

This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.

Treatment of immunologic and hematologic disorders with IGFBP alone or

This is a method for enhancing systemic tissue repair in patients with burns, trauma and peptic ulcers, as well as patients about to undergo, is undergoing or just having undergone surgery. The method comprises systemically administering to such individuals a therapeutic composition comprising IGF and IGFBP. The preferred form is IGF-I/IGFBP-3.

Growing community of inventors

El Cerrito, CA, United States of America

Christopher A Maack